Mitochondria in Cell-Based Therapy for Stroke

Ask your doctor what this means.

Mitochondria in Cell-Based Therapy for Stroke 

by

Molly Monsour

¹,

Jonah Gordon

¹,

Gavin Lockard

¹,

Adam Alayli

¹ and

Cesar V. Borlongan

^2,*

¹

University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA

²

Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA

^*

Author to whom correspondence should be addressed.

Antioxidants 2023, 12(1), 178; https://doi.org/10.3390/antiox12010178

Received: 2 January 2023 / Revised: 9 January 2023 / Accepted: 10 January 2023 / Published: 12 January 2023

(This article belongs to the Special Issue Novel Therapies of Oxidative Stress-Induced Age-Related Neurodegenerative Diseases)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Despite a relatively developed understanding of the pathophysiology underlying primary and secondary mechanisms of cell death after ischemic injury, there are few established treatments to improve stroke prognoses. A major contributor to secondary cell death is mitochondrial dysfunction. Recent advancements in cell-based therapies suggest that stem cells may be revolutionary for treating stroke, and the reestablishment of mitochondrial integrity may underlie these therapeutic benefits. In fact, functioning mitochondria are imperative for reducing oxidative damage and neuroinflammation following stroke and reperfusion injury. In this review, we will discuss the role of mitochondria in establishing the anti-oxidative effects of stem cell therapies for stroke.